Pulmatrix Q2 10-Q: Going Concern Warning, Cash Down to $2.2M, Merger Critical

summarizeSummary

Pulmatrix's Q2 10-Q shows cash down to $2.2 million and a going concern warning, making the pending Eos SENOLYTIX reverse merger the company's only clear path to survival.

check_boxKey Events · Earnings and Guidance · PULM

• Going Concern Warning

  Management states substantial doubt about the company's ability to continue as a going concern without the closing of the Eos merger, citing cash of $2.2 million and forecasted negative cash flows.

• Cash Position Deteriorates

  Cash and cash equivalents fell to $2.2 million at June 30, 2026, from $4.1 million at December 31, 2025, with an additional $0.7 million in restricted cash.

• Series B Preferred Stock Issued

  Issued 1,000 shares of Series B Convertible Preferred Stock to an Eos affiliate for $1.0 million gross proceeds; conversion price $2.20 per share, 8% cumulative dividends.

• Merger Dependency

  If the merger with Eos SENOLYTIX is not consummated, the board may pursue dissolution and liquidation; the merger would leave legacy Pulmatrix holders with only 6% of the combined company.

auto_awesomeAnalysis · PULM · Life Sciences

Pulmatrix's Q2 10-Q confirms the company's survival hinges on completing its reverse merger with Eos SENOLYTIX. Cash and equivalents fell to $2.2 million from $4.1 million at year-end, and management states there is substantial doubt about its ability to continue as a going concern without the merger closing. The filing also details a $1.0 million Series B preferred stock investment from an Eos affiliate, with $700,000 restricted until the merger closes or terminates. If the merger fails, the board may pursue dissolution and liquidation.